FreeTheAI

Regeneron Amends Sanofi Antibody Pact for $1B Upfront and Releases Libtayo Data

MixedMedium impact
REGN$746.54 0.94%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) modified its antibody agreement with Sanofi, securing $1 billion in upfront cash alongside up to $7 billion in potential milestone payments. Under the restructured terms effective October 1, 2026, the two pharmaceutical developers will split profits 50/50, while Regeneron takes charge of ongoing product development and U.S. regulatory filings.

Alongside the corporate agreement, the biotech company presented approximately 3.5-year overall survival results from its Phase 3 C-POST trial evaluating Libtayo (cemiplimab) as an adjuvant therapy for patients with high-risk cutaneous squamous cell carcinoma following surgery and radiation. Meanwhile, the drugmaker disclosed that an acquired in-process research and development charge will reduce third-quarter 2026 earnings per share by $0.18 on both a GAAP and non-GAAP basis.

Investors will be tracking how the adjusted responsibilities under the Sanofi collaboration impact future commercialization and regulatory progress in the United States. Following the announcements, shares of Regeneron Pharmaceuticals, Inc. rose 0.94% to $746.50.

Key points

  • Regeneron Pharmaceuticals, Inc. updated its antibody agreement with Sanofi, receiving $1 billion upfront and eligibility for up to $7 billion in milestone payments.
  • The revised deal includes a 50/50 profit split, with Regeneron leading development and U.S. regulatory filings effective October 1, 2026.
  • The company shared ~3.5-year Phase 3 C-POST overall survival trial data for Libtayo in post-surgery, high-risk cutaneous squamous cell carcinoma.
  • An in-process research and development charge is expected to lower third-quarter 2026 GAAP and non-GAAP earnings by $0.18 per share.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What are the details of the new Regeneron and Sanofi agreement?

Sanofi is paying Regeneron $1 billion upfront with up to $7 billion in milestone payments and a 50/50 profit split. Regeneron will lead development and U.S. regulatory efforts, with the amended pact effective October 1, 2026.

How will the recent research charge affect Regeneron's earnings?

An acquired in-process research and development charge will reduce Regeneron's third-quarter 2026 GAAP and non-GAAP earnings per share by $0.18.

What clinical trial data did Regeneron report for Libtayo?

Regeneron reported approximately 3.5-year Phase 3 C-POST overall survival data for Libtayo used as an adjuvant treatment in high-risk cutaneous squamous cell carcinoma following surgery and radiation.